Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arctic Bioscience Director's Dealing 2022

Apr 22, 2022

3536_dirs_2022-04-22_f4618d26-c3dd-4426-a6b1-af6d9836df1f.html

Director's Dealing

Open in viewer

Opens in your device viewer

Arctic Bioscience - Mandatory notification of trade

Arctic Bioscience - Mandatory notification of trade

Vartdal Holding AS, a legal person closely associated with a person discharging

managerial responsibilities in Arctic Bioscience, has today bought 12,531 shares

in Arctic Bioscience at an average price of NOK 16 per share. Following the

transaction, Vartdal Holding AS holds 1,040,286 shares in Arctic Bioscience.

Vartdal Holding AS is owned 33,33 % by Future Invest AS, which again is owned

100 % by Jan Endre Vartdal, member of the Board of Directors in Arctic

Bioscience.

In total, all legal persons closely associated with Jan Endre Vartdal, holds

1,843,887 shares in Arctic Bioscience after today's transaction.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements pursuant to

Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities

Trading Act § 5-12.

For more information, please contact

Jone R. Slinning

CFO Arctic Bioscience

Phone: +47 948 75 469

E-mail: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical and pharmaceutical products based on unique bioactive marine

compounds from herring roe.

The company is developing HRO350 - a novel investigational drug candidate based

on herring roe. HRO350 is being developed for treatment of patients with mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines with beneficial safety profile.

Herring roe contains lipids that are essential in maintaining cell membranes and

omega -3 fatty acids that contribute to the normal functioning of brain, heart,

and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk

ingredients as well as finished goods under the ROMEGA® brand. The strategy is

to switch sales from bulk to finished goods and focus markets are USA and China.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.